- Preventative health care market expected to see 15 percent CAGR in build toward $196.9 billion in revenues by 2024
- PreveCeutical Medical conducting five R&D programs that aim to boost preventative health for cancers, head injuries
- Recent investor update highlights company’s cannabis product development efforts, including sleep aid product agreement with Asterion Cannabis Inc.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) recently published an investor update detailing its corporate activities (http://nnw.fm/cV3wS), particularly as they relate to its efforts to improve public health through a novel delivery method for cannabis-related products. The report notes PreveCeutical’s successes, underscored by its completion of a $6.5 million financing to inject new capital into its research efforts, as well as general capital purposes.
PreveCeutical CEO and President Stephen Van Deventer has a long history of building up cutting edge companies, including Aurora Cannabis Inc., together with PreveCeutical co-founder Kimberly Van Deventer. Since 2015, PreveCeutical’s mission has been one of developing preventive therapies for health-conscious consumers who want nature-based products.
In recent months, the company has advanced the testing of its Nature Identical™ peptides toward the treatment and prevention of cancers such as the glioblastoma, the disease that took the life of Sen. John McCain. The company’s research team identified eight peptide candidates for the anticipated line of wellness products earlier this year, building on analysis of the Caribbean blue scorpion whose venom is widely reputed to have had a historical benefit among islanders of treating and staving off cancers.
Under the second phase of development, PreveCeutical’s researchers are working to redesign the eight venom peptides to improve their stability and usefulness in drug applications (http://nnw.fm/zRQ3i). Once that work is completed, the company will begin screening the peptides in cell-based cancer models.
PreveCeutical has been simultaneously developing its Sol-gel formulation as a nasal gel that will deliver cannabinoid solutions in a rapid-pass mechanism from the nose to the brain, avoiding the destructive aspects of the digestive system that seek to vet and eliminate chemicals that are foreign to the body.
By using Sol-gels to deliver cannabis derivatives in a non-smoked method, PreveCeutical expects to engineer better ways of responding to pain, inflammation, anxiety, seizures and other neurological disorders that cannabis has a history of alleviating. The company is currently testing several custom applicators to facilitate safe and consistent delivery of the cannabinoids to the central nervous system in defined measurements, all with the intent of creating a way to present medications directly where they will do the most good with the fewest side effects.
To further its cannabis research, PreveCeutical created an Australian subsidiary, through which the company conducts its development projects in conjunction with the Pharmacy Australia Centre of Excellence at the University of Queensland. PreveCeutical secured the licenses to have cannabis shipped from Canadian cultivators to the university earlier this year.
In mid-August, 2018, privately held Asterion Cannabis Inc., where Van Deventer also serves as CEO and board chairman, announced that it had granted PreveCeutical a worldwide license to use, manufacture, distribute and sell three natural health sleep aid products that are Health Canada-approved. The news followed on Asterion’s July announcement that it will build the world’s largest automated greenhouse in Queensland, using renewable energy to power the 4.3 million-square-foot facility (approximately 99 acres, or 40 hectares) for cannabis extraction, processing and research and development.
The company intends to begin manufacturing the Natural Health Products line of sleep aids and sell them in retail pharmacies and health-focused stores, as well as on PreveCeutical’s website.
PreveCeutical also has R&D programs targeting dual gene therapy for type 2 diabetes and obesity, non-addictive analgesic peptides as a replacement to highly addictive analgesics and a therapeutic product for treating athletes who suffer from concussions. Through these initiatives, the health sciences company aims to become a leader in preventative health sciences.
Crystal Equity Research noted that the company’s successful efforts to raise new funding in June for useable capital (http://nnw.fm/uJ7xE) put PreveCeutical’s potential “into a higher gear with its development pipeline,” predicting that preventative health care will remain lucrative as it builds toward an anticipated $196.9 billion in revenue by 2024 with a 15 percent CAGR. Grandview Research found that 60 percent of the world’s population uses some type of medicine, whether traditional or non-conventional. The National Center for Disease Control reported that 20 percent of the United States’ population uses alternative therapies (http://nnw.fm/nB5PL).
For more information, visit the company’s website at www.PreveCeutical.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
